When the donor is a brother whose cells are compatible, survival one year after transplantation is 73%, compared to about 30% in those SCU transplants from a donor unrelated to the patient.
Specifically, relapse after transplantation was not associated with the acquisition of previously unknown AML-specific mutations or structural variations in immune-related genes.
After the transplant, the authors observed no adverse effects, and four of the five patients treated showed a marked improvement of symptoms 5- 21 months after transplantation; the fifth showed incomplete remission.
The primary end point was the proportion of patients, among patients without detectable CMV DNA at randomization, who had clinically significant CMV infection through week 24 after transplantation.
日本語
中文
عربى
Български
বাংলা
Český
Dansk
Deutsch
Ελληνικά
Español
Suomi
Français
עִברִית
हिंदी
Hrvatski
Magyar
Bahasa indonesia
Italiano
Қазақ
한국어
മലയാളം
मराठी
Bahasa malay
Nederlands
Norsk
Polski
Português
Română
Русский
Slovenský
Slovenski
Српски
Svenska
தமிழ்
తెలుగు
ไทย
Tagalog
Turkce
Українська
اردو
Tiếng việt